Therefore, preclinical trial of CAL-101 inducing apoptosis in ATL cells [328] and a series of clinical trials of PI3K/AKT inhibitors are expected to offer new treatment regimens for patients with T/NK-NHL [316] (Tables 2, 3). This evidence concerns the gene PIK3CD and non-Hodgkin lymphoma.